These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642 [TBL] [Abstract][Full Text] [Related]
11. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715 [TBL] [Abstract][Full Text] [Related]
12. Is celiac axis resection justified for T4 pancreatic body cancer? Yamamoto Y; Sakamoto Y; Ban D; Shimada K; Esaki M; Nara S; Kosuge T Surgery; 2012 Jan; 151(1):61-9. PubMed ID: 22088810 [TBL] [Abstract][Full Text] [Related]
13. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma. Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385 [TBL] [Abstract][Full Text] [Related]
14. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection]. Ridwelski K; Meyer F; Schmidt U; Lippert H Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961 [TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma. Lee YN; Sung MK; Hwang DW; Park Y; Kwak BJ; Lee W; Song KB; Lee JH; Yoo C; Kim KP; Chang HM; Ryoo BY; Kim SC Cancer Res Treat; 2024 Oct; 56(4):1240-1251. PubMed ID: 38901824 [TBL] [Abstract][Full Text] [Related]
17. Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer. Helm J; Centeno BA; Coppola D; Melis M; Lloyd M; Park JY; Chen DT; Malafa MP Cancer; 2009 Sep; 115(18):4080-9. PubMed ID: 19626671 [TBL] [Abstract][Full Text] [Related]
18. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Adham M; Jaeck D; Le Borgne J; Oussoultzouglou E; Chenard-Neu MP; Mosnier JF; Scoazec JY; Mornex F; Partensky C Pancreas; 2008 Nov; 37(4):352-7. PubMed ID: 18665012 [TBL] [Abstract][Full Text] [Related]
19. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836 [TBL] [Abstract][Full Text] [Related]
20. Laparoscopic resection of exocrine carcinoma in central and distal pancreas results in a high rate of radical resections and long postoperative survival. Marangos IP; Buanes T; Røsok BI; Kazaryan AM; Rosseland AR; Grzyb K; Villanger O; Mathisen Ø; Gladhaug IP; Edwin B Surgery; 2012 May; 151(5):717-23. PubMed ID: 22284762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]